



// ERRATUM

27 de marzo de 2026

Page 57 (aTMS section)

The sentence:

“At the time of developing this CPG, these approaches were not integrated into routine clinical practice, with no aTMS protocol yet FDA-cleared (8,10).”

should be corrected because at least one accelerated TMS protocol had already received FDA clearance at that time.

A more accurate wording would be:

“At the time of developing this CPG, these approaches were not integrated into routine clinical practice. However, the FDA had already cleared the Magnus Neuromodulation System with SAINT Technology in 2022, meaning that at least one accelerated TMS protocol had received regulatory clearance in the US.”

Rationale:

The FDA granted clearance in September 2022 to the **Magnus Neuromodulation System with SAINT Technology** for major depressive disorder, which corresponds to an accelerated intermittent theta burst stimulation protocol delivered over 5 days.

